Good afternoon. A welcome to Fractal Health's second quarter 2025 financial results and business updates call. As a reminder, this conference call is being recorded. At this time, all participants are in listen-only mode. There will be a Q&A session following management prepare remarks. I'll now turn the call over to Brian Luque, Head of Investor Relations and Corporate Development at Fractal. Brian, you may now begin.

Thank you. This afternoon, we issued a press release that outlines the topics we plan to discuss today. This release is available at www.fractal.com under the Investors tab. Joining us on the call today are Dr. Harith Rajagopalan, Chief Executive Officer, and Lisa Davidson, Chief Financial Officer. During this call, we make forward-looking statements which involve risks and uncertainties that may cause actual results to differ materially from our forward-looking statements. You provide a comprehensive list of risk factors in our SEC file, including the quarterly report on Form 10-Q filed today, which I encourage you to review. Any forward-looking statements on the call are subject to substantial risks and uncertainties, speak only as of the call's original date, and we undertake no obligation to update or revise any of the statements, even if subsequent events cause the company's views to change. It It is now my pleasure to pass the call over to Harit.

Thank you, Brian. Good afternoon, everyone. Fractal is tackling the next major crisis in metabolic care, weight regain after GLP-1 discontinuation. Tens of millions of people are struggling with their weight and will start a GLP-1 with the hope of achieving lasting weight loss. But most will stop the drug within a year. Nearly all will regain weight. This rebound problem is a massive unmet need. because most patients cannot stay on drug therapy for weight loss for the rest of their lives and when they stop drug therapy not only does their weight come back but so too does their profound hunger and all of the metabolic complications associated with obesity including type 2 diabetes fractal health may be the first company with a scalable solution to this problem because our therapies target the root cause of disease for the very first time since our last earnings call, we have strengthened our balance sheet, further sharpened our strategic focus, and delivered on critical milestones. This focused execution sets us up for a transformational second half of the year. Last week, we strengthened our financial position through a $23 million underwritten public offering of common stock with accompanying warrants that could provide up to a total of $69 million in proceeds. This financing was led by leading healthcare investors, including including Nantahala Capital, 8R1 Capital Management, Second Line Capital, 683, and SilverArc, investors who understand the significance of our upcoming catalysts and chose to scale their investments alongside them. With this capital structure in place, we've positioned ourselves to fully capture the value of our clinical and strategic progress in the months ahead. With the proceeds from this primary capital raise, we expect to extend our cash runway through important Remain One midpoint cohort milestones with next month's three-month randomized data readout, as well as the six-month randomized data from this cohort in the first quarter of 2026. We sharpened our strategic focus by reducing our burn rate from $25.4 million in Q1 to 19.8 million in Q2 as we wound down our spend on non-critical programs following the strategic reprioritization earlier in the year. Going forward, we will continue to see reduced cash burn be a key area of focus with disciplined cash management through the Remain 1 pivotal study milestones ahead. We have also delivered on key milestones across our Revita and Rejuva programs during this time. Ruvida is emerging as a foundational therapy to reset the body's metabolic setpoint in obesity and type 2 diabetes. Last week, we reported new data from our German Real World Registry study that reinforced Ruvida's durability, showing up to two years of benefit in weight maintenance and blood sugar control following a single treatment. What is impressive about the new data from Germany is not only the duration of effective up to two years, but also the potency of the therapy over that period of time, with even greater improvements in body weight at two years than at one year. What this implies is that Revita can deliver real-world results that could get even better over time as the body accommodates to a more physiologic and healthy relationship with food. These long-term outcomes are consistent with prior Revita clinical studies and solidify its potential as a real-world, non-pharmacologic solution for sustained metabolic results with a broad set of potential indications in obesity and metabolic disease. Our near-term focus is solving weight regain after GLP-1 discontinuation, a challenge that is now recognized by patients, physicians, and payers alike. In June, we shared positive three-month open-label data from the Reveal-1 cohort. Patients who stopped terzepatide and received a single Revita procedure demonstrated weight stability at three months, with nearly half losing even more weight after stopping the drug. This is the first human clinical evidence that Revita may stabilize weight after stopping GLP-1s. Enrollment of our Remain 1 pivotal study is complete and randomizations are on track. We continue to see a favorable safety profile and strong procedural consistency across sites, important indicators for study success and potential commercial scale. Next month, we expect to report three-month randomized data from the Remain 1 midpoint cohort. These are people with obesity but without type 2 diabetes who have lost 15% of their total body weight with terzepatide before randomization to Revita or sham. This will be the first blinded controlled data set assessing whether Revita can preserve GLP-1-induced weight loss and metabolic benefit. The goal of the Remain 1 midpoint cohort will be to establish an early efficacy signal for Revita in a rigorous sham-controlled study ahead of our pivotal cohort for which top-line data are expected in the second half of next year. We believe this randomized midpoint data in September will be a key proof point for the therapy, and we are optimistic for a positive outcome. For the Remain One midpoint cohort readout, including the three-month readout next month, success means showing clear separation between Revita and sham on weight regain over time. More specifically, we are aiming to show that Revita performs at least 50% better than what one would expect from terzepatide withdrawal alone. Based on Surmount 4 data from Eli Lilly, patients who discontinue terzepatide typically regain 5% to 6% of their body weight by three months. If Revita-treated patients show only 3% weight regain or less at this same time point, that would not only be statistically significant, it would also be a highly meaningful result for patients, for physicians, and for payers. To put this in context, we shared three-month data from our open label Reveal 1 study in June, where the median weight regain was less than a half a percentage point or just one pound of weight change compared to the five to six percent body weight or 10 to 15 pounds of weight regain typically seen by this time point when patients stop trisepatide. That early signal of weight loss maintenance was incredibly encouraging and we believe it bodes very well and sets a strong precedent heading into the next month randomized readout from Remain One. Success with Remain One could position Revita as the LASIK for obesity, a straightforward one-time intervention that targets a root cause of disease and offers a potential for a lasting alternative to chronic disease management. This is not just theoretical. Our recent field visits to clinical trial sites and multiple advisory boards have confirmed three key themes. First, GI physicians are incredibly excited about Revita and believe it can be a valuable tool in their armamentarium as they increasingly move into treating obesity and metabolic disease. Second, based on the rapidity of enrollment in Remain One and the enthusiasm they see from patients, GI physicians anticipate significant procedure volumes upon potential FDA approval. And third, GLP-1 prescribers know that most of their patients do not want to be on these drugs for the rest of their lives, either because of side effects, costs, or concerns about long-term drug therapy. And with these insights in mind, we are building the foundation for commercial scale. In June, we announced a non-binding letter of intent with Barry Endo, a nationwide endoscopic obesity care platform to prepare for potential adoption of Revita pending FDA approval. This collaboration could help create a ready-made distribution channel across high volume ambulatory and hospital endoscopy centers. The collaboration will focus on pre-commercial preparation, including workflow design, provider education, health economic analysis, and the development of referral pathways. As we pioneer new therapeutic areas in metabolic medicine, we are also establishing a leadership position that is built to last. In June, we were granted two new U.S. patents, reinforcing our foundational innovations in duodenal mucosal resurfacing. Today, our portfolio includes over 100 granted patents throughout the world, including 32 granted U.S. patents and nearly 40 pending applications, making Fractal the clear innovation leader in gut-targeted metabolic therapy. Let me now turn to Rejuva. With Rejuva, we believe we've created a truly breakthrough therapy, the first potentially one-and-done smart GLP-1 platform designed to program pancreatic beta cells to secrete GLP-1 in response to nutrients, potentially delivering durable, physiologic, metabolic control at far lower circulating GLP-1 levels than required by injectable therapies. Rejuva 001 has completed preclinical efficacy, toxicity, and biodistribution studies. CMC manufacturing is progressing well and nearly complete. We reached agreement with regulators on the design of the Rejuva 001 Phase 1-2 clinical study. It will be an open-label, multi-center study that will evaluate the safety, tolerability, and preliminary efficacy of Rejuva 001 in adults with inadequately controlled type 2 diabetes despite multiple glucose-lowering agents. In May, we submitted the first module of our clinical trial application. Pending regulatory clearance, we expect to dose-first patients and report preliminary data in 2026. Rejuva 001 could redefine the risk-benefit profile of long-term GLP-1 therapy, and open the door to a durable, potentially curative solution for chronic metabolic disease. We believe that the future of metabolic care lies in durability, in physiologic design, and in root cause solutions that work in the real world. With Revita, we aim to be the LASIK for obesity. With Rejuva, we are reprogramming the pancreas itself for life. Our execution is tight, our focus is clear, and our opportunity is substantial. Lisa will now walk through the financials.

Thank you, Harith. In the second quarter of 2025, we continue to invest in the execution of our clinical strategy across both the Revita and Rejuva programs. R&D expense for the quarter was $21.2 million, compared to $16.8 million in the second quarter of 2024, reflecting the continued advancement of the Remain One clinical study in the Rejuva program, including personal-related costs. SG&A expense was $4.9 million, compared to $6.2 million in the same quarter last year. The reduction is primarily due to the lower stock-based compensation. Net loss for the quarter was $27.9 million, compared to $17.2 million in Q2 2024, largely due to changes in non-cash fare value of notes and warrants and increased operating expenses. As of June 30th, we had $22.3 million in cash and cash equivalents. Based on our current operating plans, and after considering the net proceeds from the underwritten public offerings. We expect our current cash position to fund operations into 2026 through key upcoming data readouts from the Remain One midpoint cohort. With that, I'll turn the call back over to Hari.

Thank you, Lisa. To wrap up, we believe Fractal is building what comes next in metabolic care. This is an exciting period of focus and execution for the business, we are entering our data-rich, catalyst-heavy stretch with momentum, focus, and capital in place. As a reminder, we have a rich set of clinical milestones ahead. Next month, we expect randomized three-month data post-terzepatide discontinuation in 45 patients randomized two to one to Revita versus Sham in the Remain 1 midpoint cohort. In the fourth quarter, we expect incremental six-month open-label data from the Reveal 1 cohort. In the first quarter of 2026, we expect six-month randomized data from the Remain 1 midpoint cohort, and the six-month time point is significant because it aligns with the time point for the registrational Remain 1 pivotal study. In the second quarter of 2026, we expect to see the first one-year open-label data from the Reveal 1 cohort, one year after stopping a GLP-1, undergoing a single treatment, and then following patients to see weight maintenance over time. And in the second half of 2026, we expect the six-month top-line primary endpoint data from the Remain 1 pivotal cohort. Also in the second half of 2026, we anticipate submitting a pre-market approval application, or PMA, with the FDA for Revita in weight maintenance. With a stronger balance sheet to execute against these exciting milestones, sharper strategic focus, and these exciting upcoming catalysts, the near-term future is bright for guts. With that, I'd like to thank the people who make this work possible. To our employees, thank you for your relentless drive and belief in our mission. To the physicians and investigators advancing our clinical programs with care and commitment, we are proud to partner with you. To the patients participating in our trials, thank you for your courage and your trust. And to our investors, thank you for your continued support and conviction. Operator, we are now ready to take questions.

Thank you. At this time, we'll conduct the question and answer session. As a reminder to ask a question, you will need to press star 11 on your telephone and wait for your name to be announced. To withdraw your question, please press star 11 again. Please stand by while we compile the Q&A roster. And our first question comes from the line of Jason Gerber of Bank of America Securities. It line is now open.

Thanks for taking my question. I guess just first on the midpoint update in September, you know, beyond, I guess, maintenance of preservation of the weight, any other, you know, data points that you guys plan to share that you just kind of flag in terms of what you think will be important in the update just beyond sort of the main efficacy measure. And will you plan to speak to any outliers in the data set? And then, you know, on Rejuva IND clearance, any status update in terms of what are the gating items there would be helpful. Thanks.

Thanks, Jason. Appreciate the question. So on the midpoint update, as a reminder, 45 patients randomized two to one to Revita versus sham, three months post-terzepatide discontinuation. We expect that patients who stop terzepatide at three months should regain five to six percent of their body weight. If we can cut that in half, we think we've got a blockbuster therapy on our hands. It's important for us in the midpoint data update to be able to provide people visibility into the things that will really matter for the pivotal studies readout in H2 2026, and in particular, safety, tolerability, and the effectiveness of weight loss maintenance. I expect that we'll continue to see the excellent safety and tolerability signals that we've already been sharing in our reveal study and all of our prior clinical work, and enough information on the dispersion of the weight maintenance effect in order for people to be able to get a critical appraisal of how things are shaping up for the pivotal study of 315 randomized patients, which is also already underway. And I think that should answer your question on outliers. It's going to be important for us to understand what we need to understand to believe that the pivotal will be successful. There are additional things that we're looking at in this Remain One midpoint cohort. Many of them don't occur at three months, but actually occur at six months. And so, as an example, there are DEXA scans that are built into the study, but they occur at baseline six and 12 months, but not at three months. There's additional laboratory measures that we're also going to be looking at as well, but you can expect to see more information on those in the months ahead. But the most important thing for right now, safety, tolerability, and effectiveness with enough visibility to understand how the overall population is behaving in a manner to look ahead to the pivotal. With respect to Rejuva IND, there's been tremendous progress behind the scenes. I know we just talked about how we filed our CTA module. The bottom line is that we are weeks away from seeing the lot release of our GMP product. All of the assays look like they have gone well and all of our other testing has gone well as well. We're wrapping up our reports and we will update you in due course, but we remain committed to the timelines that we've publicly shared, which is first preliminary data in 2026. Thank you, Jason.

Thanks. Thank you. One moment for our next questions. And our next question comes from the line of Mike Oles of Morgan Stanley. Your line is now open.

Yeah, hi. This is Rovadan from Mike. Thanks for taking our questions. As the GLP-1 market evolves, can you share any new learnings or trends that you're seeing that stand out for the outlook of Rovita and Rejuva?

Thanks.

Yeah, certainly. Thank you for the question. It's a broad question, and one could take that in a lot of different ways. Let me just talk about my personal experience in conversation with key stakeholders and how they feel about it. Two years ago, the question that patients were asking their doctors is, how do I get access to these medicines? And today, when I go and talk to prescribers, the single biggest question that they are telling me that they're hearing is, when can I stop taking this medicine? What is amazing to me is how rapidly people have completely routinized the assumption that they can lose weighed on the GLP-1 and are now asking what is next. And what I'm equally surprised about is how willingly the prescribers recognize that patients do not want to be on GLP-1 drugs for the rest of their lives. I think that bodes incredibly well for both Revita and Rejuva, but for different reasons. The other thing that I'm noticing is that the general perception of the GLP-1 category is that they are excellent drugs, but the weaknesses are becoming more clearly apparent in the real world in a manner that would not be visible from phase three studies. You may know that in our last call, we talked about the Cleveland Clinic showing that the real world effectiveness of semaglutide and terzepatide in Cleveland Clinic patients is substantially worse than how they looked in clinical trials. I will tell you that I've now visited other clinical trial sites who read that paper, have done their own analysis, and are confirming exactly that same finding. And all of these, I think, speak to the value that we can bring because the limitations that the drugs have on real-world effectiveness do not affect our disease-modifying approach. So I'll stop there. Otherwise, I could keep going. but I think the two key messages are the desire for patients to stop and a need for better real-world outcomes. Thanks. Thank you.

Thank you. One moment for our next question. Our next question comes from the line of Michael DeFiori of EverQuarrie SI. Your line is now open.

Hello, guys. This is JP in view of Michael. Congrats on the quarter, and thanks for taking our questions. The first one, among the nine patients in the two-year follow-up in Germany, three remain in the GLP-1 therapy throughout. Could you please help us understand the relative contribution of GLP-1 to the observed outcomes? And are there any notable differences in weight loss or glycemic control between the ones that stay in GLP-1 or not? And the second question also regarding the process, given the natural weight variability, Can you construe your weight measurement protocols like timing, repeatability, escape calibration, and how you account for day-to-day fluctuations? I mean, it's well known that weight can vary a lot during the day, so that's what we want to understand a little bit more about the protocol.

Sure, absolutely. So nine patients in Germany, three of them were on a GLP-1. They were on a GLP-1 when they entered the study. They've been on a GLP-1 for two years. We do not believe that there is a contribution from the GLP-1 to the weight loss seen in the patients in Germany, because when you exclude those patients, you look at the others, there's also a consistent signal of weight loss. And the profile of weight, a single treatment, early effects, and sustained results has been true across our clinical work for patients who are on any other background medical therapy. And so therefore, we believe that this is sort of an important point to make because of the evolving GLP-1 landscape and its utilization, but we do not think it affects our interpretation. With respect to weight variability, I'm going to assume that the conversation we're talking about here is around the Remain Pivotal study. And we have been very focused on all of the potential sources of variability in the trial. Measuring weight is one of them. and we have explicit quality control protocols like other companies do that are running obesity studies where the scale that the sites are using must be appropriately calibrated on a regular basis that this is accounted for and that the manner in which the weight is being measured in patients is also consistent. Nonetheless, we all know that there is some weight variability from people from time to time. I know it when I step on the scale every morning myself And so, therefore, I think that we can do what we can to control it, but human beings are what they are. Thank you very much.

Thank you. One moment for our next question. Our next question comes from the line of Whitney Aijem of Canaccord Genuway. Your line is now open.

Hey, guys. Just a quick follow-up, thinking about durability. For the Remain One midpoint cohort, will you continue to track those patients and then present updates at like nine months, 12 months, beyond that, how should we be thinking about that as like an early signal for durability ahead of the larger cohort follow-up?

So thanks, Whitney. If you go to our corporate deck on page four, you'll see our upcoming catalysts. And I'm happy to say that on the reveal one cohort, this is the open label cohort where we've already shared three-month data back in June. We'll share six-month data in Q4 and then one-year open label data in Q2 of 2026. For the remain midpoint cohort, we are currently projecting three-month data in September, which is next month, and then randomized six-month data early in Q1. We have not gone out into additional data points, but all of these patients will be followed for a year. You can reasonably expect that you will get incremental data updates over time. And all of that now helps by the time we see our six-month primary endpoint data from the pivotal cohort, there will be an ample body of six- and 12-month data to look at from Reveal 1 and the midpoint cohort in order to help inform the regulatory but also the commercial value proposition of Reveal end-weight means.

Got it. Okay.

And then I guess I was curious about longer term then, Like, will either the midpoint or the pivotal cohort be tracked longer than that, such that over time, you know, post-approval, let's say, or whatever, you could present updates on 18- and 24-month durability, or is that not something we should expect from these Well, we're excited about the two-year durability we're seeing in Germany, and the two-year durability we've seen from our prior RUVITA-1 study, and the durability we've seen in our pooled analysis in all of our type 2 diabetes studies. we think it's a major advantage of the therapy, and our intention will be to follow these patients longer and report those data as they emerge.

Okay, perfect. That's helpful. And then on the point of the DEXA scans that you mentioned that will be coming at the six-month time point, can you talk about any expectations there, either pre-clinically or just mechanistically? Like, how should we be thinking about the potential of Revita to sort of differentiate in that regard?

There is a preclinical study that I just reviewed that showed that the muscle, that the weight loss in duodenal bypass is principally a fat mass loss rather than a muscle mass loss. That is the only preclinical work that I've seen. It's not ours. So I think that one way to think about this is what is the weight regain phenotype looking like in those who are stopping trisepatide? And what will the body composition difference be in individuals with Revita, assuming that they're able to maintain that body weight loss? I have been unable to find, maybe you can tell me differently, any evidence of what happens in terzepatide withdrawal or semaglutide withdrawal in the DEXA scans of those patients who have stopped taking those medicines. We know that those trials had DEXA scans, but I don't know what they showed after the drug was stopped. Now we'll get an answer, and I'm excited to see what it has to show.

Got it. Likewise. Yeah. Okay. Perfect. Super helpful. Thanks very much.

Thank you. One moment for our next question. And our next question comes from the line of Jeffrey Cohen of Lettenberg. Your line is now open.

Good afternoon. Thanks for taking our questions. I wanted to expand upon the last question. Could you hypothesize a bit how the last discussion reflects upon BMIs as far as treatment groups, BMIs prior to your trisepatide or BMIs after treatment of trisepatide?

Sure. I mean, I think there's a study called Surmount 4 from Eli Lilly that I think may speak to this best. These are individuals who had obesity but not type 2 diabetes. They were given trisepatide for a period of 36 weeks, and then they were randomized to either discontinuation of the trisepatide or ongoing treatment with trisepatide for an additional year. Individuals who had lost body weight on trisepatide during the open-label run-in phase over the first 36-week period of time lost a little bit over 20% of their body weight. But by one month, and this is true for percent total body weight, it's also true for BMI. By one month, they had regained about 3% of their body weight. By three months, they had regained 5% to 6% of their body weight. By six months, they had regained 9% to 10% of their body weight. And by one year, they had regained, I want to say about 12% of their body weight, 11% to 12% of their body weight. And so what is true for percent total body weight is also true for BMI. And so what you can see is that these patients are losing really significant amounts of body weight. And when you tie that back to the DEXA scan, the general perception in the field is that these people are regaining mostly fat mass and not muscle mass, so that the BMI regain or the weight regain may be actually underestimating the metabolic problem caused by the weight loss and then the regain. And that's what we're hoping to be able to show we can do something about with Revita and weight maintenance.

Got it. And then one more, if I could. As far as treatment goes, what have you found to be duration time and any information you can provide on patients and their preferences and also any variations within the energy delivered and the duration of energy delivered as well as the length of the duodenum.

Okay, so, well, there's like four questions in there, Jeff. So, number one is, I'll start with the end, okay? Length of ablations. In the Remain One study, we are ablating an average of 16 centimeters length of the duodenum, or eight ablations of two centimeters each. that is slightly better than the average that we were seeing in reveal one which was an average of seven and a half or ablations per patient or 15 and definitely much better than what we had done in prior studies this is important and relevant for two reasons first it's relevant because we are not seeing any signal of safety or tolerability with higher lengths of ablation and yet we have also seen dose-dependent effects in our earlier clinical work. And so we will be analyzing the, you know, in a post hoc way, the length of oblation versus the magnitude of effect in order to further substantiate the efficacy that we've already feel like we've established with the dose response in our earlier work. And the absence of any safety and tolerability suggests that we are continuing to optimize the clinical profile here without causing any harm to patients, which is highly encouraging for us with respect to the magnitude and durability of the efficacy that can be achieved. Average procedure time as people are ablating a longer length of the duodenum is still about an hour or less. And we have, we're very pleased by the observation that as we go through the various clinical trial sites and the new physicians who are performing the procedure, we are seeing excellent clinical results and excellent quality and length of duodenal ablation, even with new users, as they are getting up to speed on the technology, which strengthens our sense for the ease of the learning curve. Now, the last point that I would make is that we're not changing the actual ablation energy delivered or the time of the energy that that ablation is delivered. So the only change that we are making is to the length of the duodenum that's ablated. And with respect to patient preference, a lot of people asked us whether they were, whether the rapid enrollment that we saw in remain was, and was simply because people who are getting free terzepatide in order to be able to enter the study. And there's two things that argue that patients are really excited about Revita. The first one is that patients were choosing the Revita weight maintenance trial over other weight loss drug therapy trials being run concurrently at clinical trial sites that had both. Second one is we have lost very few patients post-terzepatide prior to endoscopic randomization to either Revita or sham. The vast majority of the patients in this trial have continued all the way through, and both of those are very encouraging, empirical evidence for patient preference. Hope I got all those questions answered.

Super. Yeah, thanks for taking the moment. I appreciate it.

Thank you. One moment for our next question. And our next question comes from the line of William Wood of B-Value Securities. Your line is now open.

Thanks for taking our questions, and congrats on a very nice quarter. Just to clarify a couple, sort of building on what a couple other people asked, specifically for the reveal one, I know you sort of touched on this in regards to remain. It looks like you've now treated 22 patients on reveal one. When you report the six-month data, should we expect that all patients to have completed the six months, or is this going to be more of a subpopulation, say, the 13 patients that priorly treated the three-month cut? And with that six-month, you mentioned that we should get more data, specifically DEXA, and this is where you were referencing remain, but I was curious if we'll be also getting DEXA in the REVEAL trial, which could sort of tease out if there is a weight regain demonstrated what that gain is composed of. So just sort of understanding that, and then I have a very quick follow-up.

Yeah, the majority of the patients in the 22 that we're mentioning were treated early enough to be able to be followed and report six-month data in Q4. And I think it's generally in the better interest to be able to provide more data on more patients if possible. So you can expect that in the fourth quarter data. We do not have DEXA scans in the open-label cohort. We don't have anything to compare it to. And while we also reveal one is an open-label study and we are tracking weight, we at least have the historical comparator of weight regain from trisopetide withdrawal from surmount four. But as I alluded to earlier, we don't have similar data on what happens to body composition upon traceptide discontinuation. So I don't have any historical comparator there. So you're going to have to wait for the randomized data for us to be able to understand what the DEXA show and how to interpret them.

Got it. And then just to quickly verify, you noted, at least in the PR, that you expect to dose the first patients for Rajula 001 and then report preliminary data in 2026. Is that we should expect first dose and data in 2026, as in both occurring in 2026, or is it the first dose could actually occur in third quarter, fourth quarter this year, and then data in 2026?

Yeah, as stated, expecting first doses and preliminary data both in 2026.

Got it. Appreciate that, and thanks for the call. I'll hop back in the queue.

Thank you.

Thank you. I'll now turn the call back to Dr. Rajagopalan for closing remarks.

Well, thank you all for joining the call today. It's, as I said, an exciting period with a data-rich, catalyst-heavy set of quarters ahead, and our team is incredibly excited by the therapies that we're developing and the prospects for the patients in front of us. And we look forward to continuing to share our updates on our progress with all of you. And thanks very much.

This concludes today's conference call. Thank you for participating. You may now disconnect.